| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 237 | 2023 | 3168 | 20.280 |
Why?
|
| Esophagectomy | 109 | 2023 | 911 | 13.590 |
Why?
|
| Adenocarcinoma | 148 | 2023 | 7789 | 7.270 |
Why?
|
| Esophagogastric Junction | 44 | 2023 | 543 | 4.490 |
Why?
|
| Chemoradiotherapy | 56 | 2023 | 1946 | 3.380 |
Why?
|
| Lung Neoplasms | 85 | 2023 | 11538 | 2.990 |
Why?
|
| Neoplasm Staging | 111 | 2023 | 13658 | 2.980 |
Why?
|
| Pneumonectomy | 36 | 2023 | 831 | 2.910 |
Why?
|
| Neoadjuvant Therapy | 65 | 2023 | 4975 | 2.540 |
Why?
|
| Lymph Nodes | 27 | 2022 | 2967 | 2.520 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 47 | 2023 | 5319 | 2.410 |
Why?
|
| Stomach Neoplasms | 30 | 2023 | 2278 | 2.360 |
Why?
|
| Carcinoma, Squamous Cell | 48 | 2023 | 5437 | 2.260 |
Why?
|
| Chemoradiotherapy, Adjuvant | 24 | 2021 | 565 | 2.240 |
Why?
|
| Barrett Esophagus | 15 | 2021 | 569 | 2.110 |
Why?
|
| Esophagus | 15 | 2021 | 553 | 1.790 |
Why?
|
| Retrospective Studies | 169 | 2023 | 37905 | 1.700 |
Why?
|
| Postoperative Complications | 37 | 2022 | 5542 | 1.680 |
Why?
|
| Humans | 391 | 2023 | 261506 | 1.650 |
Why?
|
| Esophagoscopy | 17 | 2021 | 291 | 1.610 |
Why?
|
| Middle Aged | 222 | 2022 | 86204 | 1.490 |
Why?
|
| Neoplasm Recurrence, Local | 47 | 2022 | 10035 | 1.470 |
Why?
|
| Anastomotic Leak | 3 | 2018 | 71 | 1.470 |
Why?
|
| Aged | 200 | 2022 | 70117 | 1.450 |
Why?
|
| Lymphatic Metastasis | 40 | 2021 | 4844 | 1.440 |
Why?
|
| Male | 254 | 2022 | 123000 | 1.400 |
Why?
|
| Combined Modality Therapy | 58 | 2023 | 8865 | 1.370 |
Why?
|
| Female | 244 | 2022 | 141928 | 1.250 |
Why?
|
| Thoracic Surgery | 7 | 2022 | 295 | 1.250 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2019 | 94 | 1.230 |
Why?
|
| Jejunum | 6 | 2019 | 216 | 1.230 |
Why?
|
| Anastomosis, Surgical | 11 | 2020 | 371 | 1.210 |
Why?
|
| Surgical Flaps | 9 | 2022 | 927 | 1.150 |
Why?
|
| Fluorodeoxyglucose F18 | 18 | 2022 | 1226 | 1.110 |
Why?
|
| Prognosis | 82 | 2023 | 21713 | 1.040 |
Why?
|
| Thoracotomy | 7 | 2022 | 220 | 1.010 |
Why?
|
| Endosonography | 7 | 2015 | 536 | 1.010 |
Why?
|
| Esophageal Mucosa | 3 | 2018 | 10 | 0.990 |
Why?
|
| Aged, 80 and over | 97 | 2022 | 29902 | 0.980 |
Why?
|
| Surgeons | 5 | 2023 | 519 | 0.960 |
Why?
|
| Treatment Outcome | 83 | 2023 | 32848 | 0.950 |
Why?
|
| Preoperative Care | 15 | 2020 | 1529 | 0.950 |
Why?
|
| Positron-Emission Tomography | 23 | 2022 | 2173 | 0.940 |
Why?
|
| Follow-Up Studies | 51 | 2021 | 14889 | 0.940 |
Why?
|
| Pain, Postoperative | 5 | 2021 | 610 | 0.930 |
Why?
|
| Disease-Free Survival | 44 | 2021 | 10001 | 0.930 |
Why?
|
| Esophagoplasty | 3 | 2012 | 27 | 0.890 |
Why?
|
| Induction Chemotherapy | 10 | 2018 | 669 | 0.880 |
Why?
|
| Risk Assessment | 27 | 2021 | 6869 | 0.870 |
Why?
|
| Tracheal Neoplasms | 1 | 2022 | 42 | 0.870 |
Why?
|
| Neoplasm, Residual | 9 | 2018 | 1656 | 0.860 |
Why?
|
| Bronchial Neoplasms | 1 | 2022 | 79 | 0.850 |
Why?
|
| Salvage Therapy | 14 | 2021 | 2054 | 0.830 |
Why?
|
| Carcinoma, Signet Ring Cell | 5 | 2020 | 170 | 0.820 |
Why?
|
| Thoracic Surgical Procedures | 7 | 2022 | 261 | 0.820 |
Why?
|
| Survival Rate | 60 | 2023 | 12221 | 0.810 |
Why?
|
| Adult | 138 | 2022 | 77950 | 0.800 |
Why?
|
| Diagnostic Imaging | 2 | 2021 | 1162 | 0.800 |
Why?
|
| Esophageal Diseases | 2 | 2020 | 69 | 0.790 |
Why?
|
| Pleural Neoplasms | 9 | 2021 | 470 | 0.780 |
Why?
|
| Pain Management | 3 | 2021 | 668 | 0.770 |
Why?
|
| Lymph Node Excision | 11 | 2021 | 1959 | 0.770 |
Why?
|
| Metastasectomy | 5 | 2023 | 200 | 0.750 |
Why?
|
| Survival Analysis | 42 | 2021 | 9180 | 0.750 |
Why?
|
| Bupivacaine | 1 | 2020 | 68 | 0.740 |
Why?
|
| Patient Selection | 8 | 2021 | 2055 | 0.740 |
Why?
|
| Ablation Techniques | 3 | 2018 | 148 | 0.740 |
Why?
|
| Thoracic Neoplasms | 5 | 2020 | 337 | 0.720 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2018 | 7551 | 0.690 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 162 | 0.680 |
Why?
|
| Proportional Hazards Models | 23 | 2022 | 4988 | 0.680 |
Why?
|
| Microwaves | 1 | 2018 | 32 | 0.670 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 90 | 0.670 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2019 | 500 | 0.660 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2022 | 421 | 0.660 |
Why?
|
| Biomarkers, Tumor | 16 | 2021 | 10331 | 0.650 |
Why?
|
| Creativity | 1 | 2018 | 13 | 0.650 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2020 | 6207 | 0.650 |
Why?
|
| Time Factors | 29 | 2021 | 12926 | 0.640 |
Why?
|
| Databases, Factual | 17 | 2020 | 2218 | 0.620 |
Why?
|
| Thoracic Wall | 3 | 2020 | 183 | 0.620 |
Why?
|
| Propensity Score | 13 | 2021 | 750 | 0.610 |
Why?
|
| Thoracic Surgery, Video-Assisted | 9 | 2022 | 209 | 0.610 |
Why?
|
| Radiotherapy, Intensity-Modulated | 10 | 2020 | 2104 | 0.600 |
Why?
|
| Patient Discharge | 8 | 2022 | 661 | 0.600 |
Why?
|
| Positron Emission Tomography Computed Tomography | 9 | 2022 | 833 | 0.590 |
Why?
|
| Mesothelioma | 8 | 2022 | 544 | 0.590 |
Why?
|
| Gastrectomy | 8 | 2023 | 451 | 0.580 |
Why?
|
| Trachea | 1 | 2018 | 259 | 0.560 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 821 | 0.560 |
Why?
|
| Osteoclasts | 9 | 2010 | 165 | 0.550 |
Why?
|
| Hernia, Diaphragmatic | 2 | 2013 | 121 | 0.540 |
Why?
|
| Nomograms | 7 | 2020 | 313 | 0.540 |
Why?
|
| Postoperative Care | 6 | 2021 | 739 | 0.540 |
Why?
|
| Radiosurgery | 4 | 2019 | 1330 | 0.540 |
Why?
|
| Anilides | 1 | 2017 | 268 | 0.530 |
Why?
|
| Smoking Cessation | 1 | 2021 | 712 | 0.530 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 739 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2017 | 8873 | 0.520 |
Why?
|
| Robotic Surgical Procedures | 5 | 2021 | 481 | 0.520 |
Why?
|
| RNA, Neoplasm | 1 | 2017 | 771 | 0.510 |
Why?
|
| Precancerous Conditions | 3 | 2018 | 1058 | 0.510 |
Why?
|
| Prospective Studies | 25 | 2021 | 12873 | 0.510 |
Why?
|
| Neoplasm Invasiveness | 20 | 2020 | 3981 | 0.500 |
Why?
|
| Radiopharmaceuticals | 10 | 2022 | 1301 | 0.500 |
Why?
|
| Cohort Studies | 26 | 2023 | 9244 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 419 | 0.490 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.490 |
Why?
|
| Analgesics, Opioid | 6 | 2021 | 1371 | 0.490 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 2594 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2023 | 15862 | 0.470 |
Why?
|
| Thymus Neoplasms | 3 | 2020 | 400 | 0.460 |
Why?
|
| Diaphragm | 2 | 2017 | 181 | 0.460 |
Why?
|
| Tobacco Use | 1 | 2013 | 54 | 0.450 |
Why?
|
| Proton Therapy | 8 | 2020 | 1577 | 0.450 |
Why?
|
| Logistic Models | 14 | 2020 | 3441 | 0.440 |
Why?
|
| Colorectal Neoplasms | 8 | 2023 | 3578 | 0.440 |
Why?
|
| Macrophage Colony-Stimulating Factor | 5 | 1998 | 72 | 0.440 |
Why?
|
| Taxoids | 7 | 2020 | 967 | 0.440 |
Why?
|
| Incidence | 10 | 2021 | 5673 | 0.440 |
Why?
|
| Risk Factors | 28 | 2023 | 17523 | 0.420 |
Why?
|
| Texas | 20 | 2020 | 6311 | 0.420 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2012 | 32 | 0.420 |
Why?
|
| Venous Thromboembolism | 3 | 2022 | 335 | 0.420 |
Why?
|
| Multivariate Analysis | 17 | 2019 | 4298 | 0.410 |
Why?
|
| Receptor, ErbB-2 | 3 | 2019 | 2518 | 0.410 |
Why?
|
| Omentum | 1 | 2012 | 96 | 0.410 |
Why?
|
| Stomach | 2 | 2012 | 387 | 0.410 |
Why?
|
| Hospital Costs | 1 | 2013 | 228 | 0.410 |
Why?
|
| Carcinoma | 7 | 2022 | 2578 | 0.410 |
Why?
|
| Research Design | 2 | 2018 | 1544 | 0.380 |
Why?
|
| Neoplasm Metastasis | 10 | 2021 | 5112 | 0.380 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2016 | 716 | 0.380 |
Why?
|
| Hospital Mortality | 2 | 2018 | 1274 | 0.370 |
Why?
|
| United States | 22 | 2023 | 15433 | 0.370 |
Why?
|
| eIF-2 Kinase | 4 | 2015 | 164 | 0.360 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2011 | 551 | 0.360 |
Why?
|
| Mediastinitis | 1 | 2009 | 22 | 0.360 |
Why?
|
| Young Adult | 28 | 2021 | 21445 | 0.350 |
Why?
|
| Esophageal Fistula | 1 | 2009 | 27 | 0.350 |
Why?
|
| Lung Diseases | 5 | 2021 | 717 | 0.350 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 915 | 0.350 |
Why?
|
| Reoperation | 8 | 2019 | 1382 | 0.330 |
Why?
|
| Cancer Care Facilities | 7 | 2020 | 884 | 0.330 |
Why?
|
| Muscle Neoplasms | 1 | 2009 | 109 | 0.330 |
Why?
|
| Simulation Training | 2 | 2021 | 149 | 0.330 |
Why?
|
| Colon | 1 | 2012 | 670 | 0.330 |
Why?
|
| Radiation Oncology | 2 | 2023 | 529 | 0.320 |
Why?
|
| Societies, Medical | 4 | 2020 | 1335 | 0.320 |
Why?
|
| Consensus | 4 | 2021 | 978 | 0.310 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2009 | 690 | 0.310 |
Why?
|
| Polytetrafluoroethylene | 2 | 2017 | 113 | 0.300 |
Why?
|
| Fluorouracil | 10 | 2019 | 1944 | 0.300 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 992 | 0.300 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2011 | 690 | 0.290 |
Why?
|
| Lymphedema | 2 | 2022 | 239 | 0.290 |
Why?
|
| Surgical Mesh | 3 | 2017 | 209 | 0.290 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 423 | 0.280 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 394 | 0.280 |
Why?
|
| Preoperative Period | 6 | 2018 | 344 | 0.280 |
Why?
|
| Computer Simulation | 3 | 2021 | 1529 | 0.270 |
Why?
|
| Antineoplastic Agents | 15 | 2021 | 14289 | 0.270 |
Why?
|
| ErbB Receptors | 5 | 2020 | 2295 | 0.260 |
Why?
|
| Ipilimumab | 4 | 2023 | 710 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2021 | 3890 | 0.260 |
Why?
|
| Mucous Membrane | 5 | 2015 | 271 | 0.260 |
Why?
|
| RNA, Messenger | 14 | 2017 | 6150 | 0.260 |
Why?
|
| Cryosurgery | 2 | 2018 | 167 | 0.250 |
Why?
|
| Cisplatin | 7 | 2017 | 2432 | 0.250 |
Why?
|
| Disease Management | 2 | 2020 | 1052 | 0.250 |
Why?
|
| Organ Sparing Treatments | 2 | 2016 | 277 | 0.240 |
Why?
|
| SEER Program | 5 | 2019 | 1000 | 0.240 |
Why?
|
| Sensitivity and Specificity | 12 | 2018 | 4971 | 0.240 |
Why?
|
| Macrophages | 7 | 2020 | 1304 | 0.240 |
Why?
|
| Organs at Risk | 3 | 2012 | 514 | 0.240 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2013 | 275 | 0.240 |
Why?
|
| Transforming Growth Factor beta | 4 | 2016 | 1130 | 0.240 |
Why?
|
| Sepsis | 1 | 2009 | 652 | 0.230 |
Why?
|
| Radiotherapy, Conformal | 4 | 2015 | 902 | 0.230 |
Why?
|
| Bridged-Ring Compounds | 3 | 2020 | 183 | 0.230 |
Why?
|
| Neoplasm Grading | 7 | 2018 | 1742 | 0.230 |
Why?
|
| Multimodal Imaging | 4 | 2015 | 550 | 0.230 |
Why?
|
| Platinum Compounds | 3 | 2020 | 131 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 2 | 2013 | 89 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2013 | 60 | 0.230 |
Why?
|
| Tumor Burden | 8 | 2020 | 1987 | 0.220 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 1323 | 0.220 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 7222 | 0.220 |
Why?
|
| Anticoagulants | 4 | 2022 | 787 | 0.220 |
Why?
|
| SOX9 Transcription Factor | 2 | 2014 | 170 | 0.220 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 85 | 0.210 |
Why?
|
| Melanoma | 4 | 2023 | 5317 | 0.210 |
Why?
|
| Mesentery | 2 | 2022 | 72 | 0.210 |
Why?
|
| Cell Proliferation | 11 | 2017 | 7226 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2017 | 2231 | 0.200 |
Why?
|
| Analysis of Variance | 5 | 2018 | 2307 | 0.200 |
Why?
|
| Pleura | 2 | 2021 | 127 | 0.200 |
Why?
|
| Microfilament Proteins | 2 | 2016 | 487 | 0.200 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 24 | 0.200 |
Why?
|
| Lung | 9 | 2023 | 3151 | 0.200 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 14551 | 0.200 |
Why?
|
| Chest Tubes | 1 | 2021 | 101 | 0.200 |
Why?
|
| Comorbidity | 4 | 2016 | 2352 | 0.200 |
Why?
|
| Organoplatinum Compounds | 5 | 2016 | 702 | 0.190 |
Why?
|
| Phosphoproteins | 3 | 2017 | 1152 | 0.190 |
Why?
|
| Gossypol | 1 | 2021 | 28 | 0.190 |
Why?
|
| Intercostal Nerves | 1 | 2020 | 33 | 0.190 |
Why?
|
| Predictive Value of Tests | 12 | 2020 | 4892 | 0.190 |
Why?
|
| Blotting, Western | 6 | 2017 | 3536 | 0.190 |
Why?
|
| Surveys and Questionnaires | 7 | 2023 | 5687 | 0.190 |
Why?
|
| Metaplasia | 2 | 2021 | 383 | 0.190 |
Why?
|
| Perioperative Care | 3 | 2019 | 451 | 0.190 |
Why?
|
| Length of Stay | 3 | 2018 | 1900 | 0.190 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 538 | 0.190 |
Why?
|
| Esophageal Motility Disorders | 1 | 2020 | 9 | 0.190 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2017 | 297 | 0.190 |
Why?
|
| Patient Readmission | 3 | 2021 | 548 | 0.190 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2000 | 14 | 0.190 |
Why?
|
| Endoleak | 1 | 2020 | 17 | 0.190 |
Why?
|
| Ketorolac | 1 | 2020 | 20 | 0.180 |
Why?
|
| Disease Progression | 8 | 2020 | 6682 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 1439 | 0.180 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 2864 | 0.180 |
Why?
|
| Odds Ratio | 5 | 2021 | 2316 | 0.180 |
Why?
|
| Watchful Waiting | 1 | 2022 | 289 | 0.180 |
Why?
|
| Radiation Injuries | 4 | 2017 | 1411 | 0.180 |
Why?
|
| Neoplastic Stem Cells | 2 | 2021 | 1443 | 0.180 |
Why?
|
| Mutation | 6 | 2019 | 15179 | 0.180 |
Why?
|
| Radiography, Thoracic | 3 | 2017 | 462 | 0.180 |
Why?
|
| Lymphocytes | 2 | 2023 | 1234 | 0.180 |
Why?
|
| Rare Diseases | 1 | 2022 | 351 | 0.180 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 163 | 0.170 |
Why?
|
| Treatment Failure | 7 | 2019 | 1391 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 3821 | 0.170 |
Why?
|
| Learning Curve | 1 | 2019 | 68 | 0.170 |
Why?
|
| Flow Cytometry | 4 | 2017 | 3033 | 0.170 |
Why?
|
| Animals | 32 | 2021 | 59536 | 0.170 |
Why?
|
| Carrier Proteins | 4 | 2016 | 2022 | 0.170 |
Why?
|
| Paneth Cells | 1 | 2019 | 23 | 0.170 |
Why?
|
| Bone Development | 2 | 1999 | 83 | 0.170 |
Why?
|
| Age Factors | 7 | 2020 | 5377 | 0.170 |
Why?
|
| Aftercare | 4 | 2022 | 259 | 0.170 |
Why?
|
| Radiotherapy | 5 | 2014 | 1824 | 0.170 |
Why?
|
| Bayes Theorem | 2 | 2021 | 1021 | 0.170 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2017 | 388 | 0.170 |
Why?
|
| Sarcoma | 3 | 2018 | 1725 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 709 | 0.170 |
Why?
|
| Sweating | 1 | 2018 | 10 | 0.170 |
Why?
|
| Nerve Block | 1 | 2020 | 176 | 0.160 |
Why?
|
| Alloys | 1 | 2018 | 32 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 524 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 521 | 0.160 |
Why?
|
| Colostomy | 1 | 1998 | 70 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 1350 | 0.160 |
Why?
|
| Biopsy | 6 | 2020 | 3443 | 0.160 |
Why?
|
| Neutrophils | 1 | 2023 | 835 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 384 | 0.160 |
Why?
|
| GABA Agents | 1 | 2018 | 26 | 0.160 |
Why?
|
| Nutrition Therapy | 1 | 2018 | 21 | 0.160 |
Why?
|
| Rectal Prolapse | 1 | 1997 | 5 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 267 | 0.160 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2010 | 270 | 0.160 |
Why?
|
| Metatarsal Bones | 4 | 1999 | 9 | 0.160 |
Why?
|
| Natural Language Processing | 1 | 2018 | 119 | 0.150 |
Why?
|
| Radiotherapy Dosage | 9 | 2019 | 3842 | 0.150 |
Why?
|
| Robotics | 1 | 2021 | 359 | 0.150 |
Why?
|
| Sucrose | 1 | 1997 | 64 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 360 | 0.150 |
Why?
|
| Mediastinum | 1 | 2019 | 268 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 126 | 0.150 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 111 | 0.150 |
Why?
|
| Ticlopidine | 1 | 2017 | 95 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 2 | 2012 | 5061 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 383 | 0.150 |
Why?
|
| Blood Component Removal | 1 | 2017 | 121 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.150 |
Why?
|
| Intraoperative Care | 1 | 2018 | 259 | 0.150 |
Why?
|
| Benchmarking | 1 | 2019 | 273 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2017 | 64 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2020 | 953 | 0.140 |
Why?
|
| Valproic Acid | 1 | 2018 | 263 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 598 | 0.140 |
Why?
|
| Calcium | 1 | 2013 | 1537 | 0.140 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 147 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2017 | 138 | 0.140 |
Why?
|
| Cell Differentiation | 7 | 2017 | 4078 | 0.140 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 6009 | 0.140 |
Why?
|
| Photons | 2 | 2017 | 507 | 0.140 |
Why?
|
| International Cooperation | 2 | 2015 | 323 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 852 | 0.140 |
Why?
|
| Bone Resorption | 2 | 2007 | 138 | 0.140 |
Why?
|
| Smad3 Protein | 2 | 2016 | 129 | 0.140 |
Why?
|
| Flavonoids | 1 | 2017 | 188 | 0.140 |
Why?
|
| Teaching | 1 | 2018 | 243 | 0.140 |
Why?
|
| Hernia, Ventral | 1 | 1998 | 159 | 0.140 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 313 | 0.140 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 1995 | 12 | 0.140 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2015 | 14 | 0.140 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2016 | 38 | 0.140 |
Why?
|
| Precision Medicine | 3 | 2020 | 1154 | 0.140 |
Why?
|
| Carcinoid Tumor | 1 | 2018 | 280 | 0.130 |
Why?
|
| Signal Transduction | 7 | 2018 | 11965 | 0.130 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 355 | 0.130 |
Why?
|
| Heart Neoplasms | 1 | 2018 | 214 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2017 | 103 | 0.130 |
Why?
|
| Lymphopenia | 1 | 2017 | 199 | 0.130 |
Why?
|
| Up-Regulation | 3 | 2017 | 2450 | 0.130 |
Why?
|
| Serous Membrane | 1 | 2015 | 9 | 0.130 |
Why?
|
| Obesity | 4 | 2017 | 2884 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 256 | 0.130 |
Why?
|
| Radiologists | 1 | 2017 | 163 | 0.130 |
Why?
|
| Remission Induction | 7 | 2017 | 3569 | 0.130 |
Why?
|
| Mice | 22 | 2021 | 34495 | 0.130 |
Why?
|
| Cause of Death | 2 | 2015 | 752 | 0.130 |
Why?
|
| Immunohistochemistry | 8 | 2021 | 7548 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2015 | 75 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 403 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2019 | 712 | 0.130 |
Why?
|
| Treatment Refusal | 2 | 2013 | 128 | 0.130 |
Why?
|
| Endoscopy | 1 | 2018 | 479 | 0.130 |
Why?
|
| beta Catenin | 1 | 2019 | 688 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 600 | 0.130 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 235 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 671 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1493 | 0.120 |
Why?
|
| Delphi Technique | 3 | 2021 | 210 | 0.120 |
Why?
|
| Statistics, Nonparametric | 4 | 2020 | 980 | 0.120 |
Why?
|
| Piperidines | 2 | 2017 | 1035 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 577 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 2330 | 0.120 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 1022 | 0.120 |
Why?
|
| Neoplasms | 5 | 2023 | 15193 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 444 | 0.120 |
Why?
|
| Methylprednisolone | 1 | 1994 | 193 | 0.120 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1070 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 104 | 0.120 |
Why?
|
| Cell Nucleus | 2 | 2017 | 1620 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 225 | 0.120 |
Why?
|
| Self Report | 2 | 2023 | 756 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1331 | 0.120 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 577 | 0.120 |
Why?
|
| Glucose | 2 | 2021 | 1248 | 0.120 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 91 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 2403 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 1533 | 0.110 |
Why?
|
| Pyrimidines | 3 | 2016 | 3518 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 6 | 2016 | 2370 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 450 | 0.110 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1992 | 17 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2020 | 5178 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2019 | 1863 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 621 | 0.110 |
Why?
|
| Prodrugs | 1 | 2014 | 217 | 0.110 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 161 | 0.110 |
Why?
|
| Osteonectin | 3 | 2010 | 53 | 0.110 |
Why?
|
| Data Collection | 1 | 2015 | 620 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2021 | 1225 | 0.110 |
Why?
|
| Intersectoral Collaboration | 3 | 2016 | 44 | 0.110 |
Why?
|
| Manometry | 1 | 2012 | 74 | 0.110 |
Why?
|
| Metformin | 2 | 2015 | 378 | 0.110 |
Why?
|
| Pressure | 1 | 2012 | 215 | 0.110 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 413 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.100 |
Why?
|
| Folate Receptor 1 | 1 | 2012 | 62 | 0.100 |
Why?
|
| Costs and Cost Analysis | 2 | 2010 | 306 | 0.100 |
Why?
|
| Gastrointestinal Motility | 1 | 2012 | 92 | 0.100 |
Why?
|
| Telephone | 3 | 2021 | 163 | 0.100 |
Why?
|
| Smoking | 1 | 2021 | 2440 | 0.100 |
Why?
|
| Sex Factors | 4 | 2020 | 2139 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1910 | 0.100 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 4849 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1866 | 0.100 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 1390 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 218 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 5 | 2015 | 1165 | 0.100 |
Why?
|
| Vaccinia virus | 2 | 2008 | 79 | 0.100 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2011 | 92 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 3719 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2013 | 6100 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 899 | 0.100 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 672 | 0.100 |
Why?
|
| Isoenzymes | 1 | 2013 | 614 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 3639 | 0.100 |
Why?
|
| Microvessels | 1 | 2012 | 135 | 0.100 |
Why?
|
| Dumping Syndrome | 1 | 2010 | 7 | 0.100 |
Why?
|
| Indoles | 2 | 2014 | 1009 | 0.100 |
Why?
|
| Intestine, Small | 1 | 1994 | 499 | 0.100 |
Why?
|
| NF-kappa B | 2 | 2008 | 1549 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 581 | 0.100 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 250 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2017 | 1171 | 0.100 |
Why?
|
| Catheter Ablation | 2 | 2013 | 620 | 0.090 |
Why?
|
| Registries | 4 | 2021 | 2170 | 0.090 |
Why?
|
| Ceramics | 1 | 2010 | 11 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 305 | 0.090 |
Why?
|
| Calcium Phosphates | 1 | 2010 | 19 | 0.090 |
Why?
|
| Adolescent | 11 | 2021 | 31252 | 0.090 |
Why?
|
| Cancer Survivors | 1 | 2017 | 650 | 0.090 |
Why?
|
| Bone Regeneration | 1 | 2010 | 32 | 0.090 |
Why?
|
| Reminder Systems | 1 | 2011 | 83 | 0.090 |
Why?
|
| Radiation Tolerance | 3 | 2020 | 629 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 4938 | 0.090 |
Why?
|
| Skull | 4 | 2010 | 231 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 498 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2013 | 889 | 0.090 |
Why?
|
| Esophageal Perforation | 1 | 2009 | 25 | 0.090 |
Why?
|
| Mice, SCID | 3 | 2019 | 1869 | 0.090 |
Why?
|
| Heterografts | 3 | 2019 | 733 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 2326 | 0.090 |
Why?
|
| Mice, Nude | 5 | 2017 | 4307 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2013 | 2203 | 0.090 |
Why?
|
| Osteogenesis | 2 | 2010 | 271 | 0.090 |
Why?
|
| Thiazoles | 1 | 2013 | 726 | 0.090 |
Why?
|
| Transfection | 2 | 2014 | 2944 | 0.080 |
Why?
|
| Wound Healing | 2 | 2010 | 815 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 3472 | 0.080 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.080 |
Why?
|
| Apoptosis | 5 | 2021 | 7591 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2008 | 33 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2014 | 2947 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 4744 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 135 | 0.080 |
Why?
|
| Collagen | 5 | 2010 | 752 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 586 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 3022 | 0.080 |
Why?
|
| Overweight | 1 | 2011 | 484 | 0.080 |
Why?
|
| Virus Replication | 2 | 2008 | 709 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2021 | 3341 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 345 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 622 | 0.080 |
Why?
|
| Thymoma | 1 | 2011 | 246 | 0.080 |
Why?
|
| Capecitabine | 2 | 2019 | 388 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 327 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2011 | 383 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 334 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 252 | 0.080 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2007 | 29 | 0.080 |
Why?
|
| Parathyroidectomy | 1 | 2009 | 203 | 0.080 |
Why?
|
| In Situ Hybridization | 5 | 1999 | 1037 | 0.080 |
Why?
|
| Parathyroid Neoplasms | 1 | 2009 | 185 | 0.080 |
Why?
|
| Cell Survival | 4 | 2017 | 3045 | 0.080 |
Why?
|
| Calcification, Physiologic | 3 | 1996 | 56 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 1054 | 0.080 |
Why?
|
| Glycolysis | 2 | 2020 | 519 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 602 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 311 | 0.070 |
Why?
|
| Pneumonia, Aspiration | 1 | 2006 | 41 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 3230 | 0.070 |
Why?
|
| Annexin A1 | 1 | 2006 | 39 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2007 | 145 | 0.070 |
Why?
|
| Medicare | 3 | 2019 | 860 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2009 | 429 | 0.070 |
Why?
|
| Cell Movement | 2 | 2013 | 2466 | 0.070 |
Why?
|
| Phosphorylation | 5 | 2013 | 4804 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2007 | 1538 | 0.070 |
Why?
|
| Ulcer | 1 | 2006 | 78 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2007 | 272 | 0.070 |
Why?
|
| Oncolytic Viruses | 1 | 2008 | 204 | 0.070 |
Why?
|
| Sialoglycoproteins | 4 | 1999 | 151 | 0.070 |
Why?
|
| Gene Expression | 4 | 2013 | 3570 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2014 | 1471 | 0.070 |
Why?
|
| Cells, Cultured | 7 | 2010 | 5637 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2007 | 167 | 0.070 |
Why?
|
| Osteopontin | 4 | 1999 | 148 | 0.070 |
Why?
|
| DNA Primers | 2 | 2013 | 1399 | 0.070 |
Why?
|
| Osteopetrosis | 3 | 1995 | 26 | 0.060 |
Why?
|
| Medical Oncology | 3 | 2022 | 1423 | 0.060 |
Why?
|
| Cell Division | 4 | 1998 | 2489 | 0.060 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2005 | 129 | 0.060 |
Why?
|
| Telemedicine | 1 | 2011 | 471 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 2015 | 5395 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2195 | 0.060 |
Why?
|
| Cytokines | 3 | 2020 | 2809 | 0.060 |
Why?
|
| Mitosis | 2 | 1998 | 615 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 482 | 0.060 |
Why?
|
| Cetuximab | 2 | 2020 | 472 | 0.060 |
Why?
|
| Quality of Life | 3 | 2023 | 4532 | 0.060 |
Why?
|
| Fibroblasts | 4 | 2019 | 1682 | 0.060 |
Why?
|
| Adenoma | 1 | 2009 | 716 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2508 | 0.060 |
Why?
|
| Mitotic Index | 2 | 2017 | 162 | 0.060 |
Why?
|
| DNA Repair | 1 | 2012 | 1872 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2009 | 631 | 0.060 |
Why?
|
| Computational Biology | 2 | 2021 | 1271 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 1005 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 4549 | 0.060 |
Why?
|
| RNA, Small Interfering | 3 | 2017 | 2216 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2007 | 410 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 2315 | 0.060 |
Why?
|
| Radiography | 3 | 2013 | 1904 | 0.060 |
Why?
|
| Myoblasts | 1 | 2013 | 72 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1960 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 5 | 2011 | 4367 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 2232 | 0.060 |
Why?
|
| Tissue Array Analysis | 3 | 2012 | 760 | 0.050 |
Why?
|
| Patient Generated Health Data | 1 | 2022 | 2 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 1248 | 0.050 |
Why?
|
| Income | 1 | 2023 | 222 | 0.050 |
Why?
|
| Histones | 1 | 2009 | 1466 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 1085 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1008 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 1303 | 0.050 |
Why?
|
| Prostheses and Implants | 2 | 2017 | 295 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 103 | 0.050 |
Why?
|
| Liver | 3 | 2022 | 2961 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 65 | 0.050 |
Why?
|
| Proteoglycans | 2 | 2010 | 259 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2021 | 1818 | 0.050 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 550 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2022 | 87 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5710 | 0.050 |
Why?
|
| Paclitaxel | 3 | 2016 | 1996 | 0.050 |
Why?
|
| Observer Variation | 2 | 2017 | 671 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2022 | 158 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2012 | 1724 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 1546 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2022 | 190 | 0.050 |
Why?
|
| Heart | 3 | 2012 | 1223 | 0.050 |
Why?
|
| Transcription, Genetic | 3 | 1999 | 3154 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 769 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2014 | 355 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 1998 | 1498 | 0.050 |
Why?
|
| Neck | 1 | 2022 | 383 | 0.050 |
Why?
|
| Thymectomy | 1 | 2020 | 79 | 0.050 |
Why?
|
| Insufflation | 1 | 2000 | 25 | 0.050 |
Why?
|
| Osteoblasts | 2 | 1994 | 370 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2020 | 94 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 2000 | 66 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 400 | 0.040 |
Why?
|
| Animals, Newborn | 3 | 1999 | 1338 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 486 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 485 | 0.040 |
Why?
|
| North America | 1 | 2020 | 314 | 0.040 |
Why?
|
| Drainage | 1 | 2021 | 416 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 289 | 0.040 |
Why?
|
| Suture Techniques | 2 | 2007 | 319 | 0.040 |
Why?
|
| Quinazolines | 2 | 2014 | 923 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 203 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 206 | 0.040 |
Why?
|
| Surgical Stomas | 1 | 1998 | 20 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 764 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 3251 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2016 | 107 | 0.040 |
Why?
|
| Osteocalcin | 4 | 2007 | 87 | 0.040 |
Why?
|
| RNA, Double-Stranded | 2 | 2008 | 79 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 217 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 1062 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 1217 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 1999 | 157 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 528 | 0.040 |
Why?
|
| Rabbits | 3 | 1997 | 957 | 0.040 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2017 | 23 | 0.040 |
Why?
|
| Administration, Rectal | 1 | 1997 | 13 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 4757 | 0.040 |
Why?
|
| Immune System | 1 | 2019 | 279 | 0.040 |
Why?
|
| Hospitals, Group Practice | 1 | 2017 | 2 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 2 | 1996 | 315 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 2314 | 0.040 |
Why?
|
| Dialysis | 1 | 2017 | 23 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2013 | 1694 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2013 | 1764 | 0.040 |
Why?
|
| Galectins | 1 | 2017 | 71 | 0.040 |
Why?
|
| Transcription Factors | 3 | 2017 | 5270 | 0.040 |
Why?
|
| Abdomen | 2 | 2012 | 332 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 4557 | 0.040 |
Why?
|
| Osteoprotegerin | 2 | 2007 | 24 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 251 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 208 | 0.040 |
Why?
|
| Administration, Topical | 1 | 1997 | 257 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 1258 | 0.040 |
Why?
|
| Molar | 1 | 1996 | 12 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2022 | 779 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 254 | 0.040 |
Why?
|
| Azepines | 1 | 2017 | 124 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 905 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 3203 | 0.040 |
Why?
|
| Safety | 1 | 1998 | 465 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 1020 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1519 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 1998 | 329 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 756 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1681 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2017 | 294 | 0.040 |
Why?
|
| CCCTC-Binding Factor | 1 | 2016 | 33 | 0.030 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2016 | 20 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2017 | 181 | 0.030 |
Why?
|
| RANK Ligand | 2 | 2007 | 119 | 0.030 |
Why?
|
| Bone and Bones | 2 | 2010 | 619 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2017 | 329 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 106 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2016 | 64 | 0.030 |
Why?
|
| Emergencies | 1 | 1997 | 202 | 0.030 |
Why?
|
| Graft Survival | 1 | 2019 | 1062 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2017 | 275 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 155 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2016 | 155 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 457 | 0.030 |
Why?
|
| Edema | 1 | 1997 | 267 | 0.030 |
Why?
|
| Telemetry | 1 | 2015 | 39 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Lactates | 1 | 2015 | 112 | 0.030 |
Why?
|
| Porphyrins | 1 | 2015 | 37 | 0.030 |
Why?
|
| Adenosine Monophosphate | 1 | 2015 | 76 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1997 | 347 | 0.030 |
Why?
|
| Prevalence | 2 | 2017 | 3260 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 834 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2008 | 1643 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 216 | 0.030 |
Why?
|
| Thyroxine | 1 | 2015 | 116 | 0.030 |
Why?
|
| Tensile Strength | 1 | 1994 | 73 | 0.030 |
Why?
|
| Polyglycolic Acid | 1 | 1994 | 34 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 424 | 0.030 |
Why?
|
| Gestational Age | 1 | 1998 | 1069 | 0.030 |
Why?
|
| Rats | 3 | 2000 | 6086 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1163 | 0.030 |
Why?
|
| Drug Stability | 1 | 2014 | 105 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1994 | 123 | 0.030 |
Why?
|
| Materials Testing | 1 | 1994 | 116 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 208 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 703 | 0.030 |
Why?
|
| Threonine | 1 | 2014 | 161 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 531 | 0.030 |
Why?
|
| Machine Learning | 1 | 2017 | 319 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 1541 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 1994 | 104 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 323 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 402 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1658 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 159 | 0.030 |
Why?
|
| Benzodioxoles | 1 | 2013 | 29 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1648 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 397 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2283 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2017 | 2819 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 151 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 231 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 1204 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 68 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1294 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 226 | 0.030 |
Why?
|
| Triazoles | 1 | 2017 | 617 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 515 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 289 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2015 | 204 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 1994 | 486 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 810 | 0.030 |
Why?
|
| Random Allocation | 1 | 1994 | 703 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 571 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 467 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 699 | 0.030 |
Why?
|
| Replication Protein C | 1 | 2012 | 18 | 0.030 |
Why?
|
| Telomerase | 1 | 2016 | 525 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 566 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2012 | 38 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1270 | 0.030 |
Why?
|
| Palliative Care | 2 | 2016 | 2037 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2013 | 241 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 931 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 134 | 0.030 |
Why?
|
| Foot | 1 | 1992 | 104 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2015 | 395 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 245 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2012 | 133 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 348 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 591 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 984 | 0.020 |
Why?
|
| Adenine | 1 | 2014 | 631 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 3976 | 0.020 |
Why?
|
| Transcription Factor HES-1 | 1 | 2011 | 49 | 0.020 |
Why?
|
| Vasodilation | 1 | 2012 | 205 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 851 | 0.020 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2011 | 32 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2011 | 85 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1945 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 214 | 0.020 |
Why?
|
| Standard of Care | 1 | 2012 | 243 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2011 | 101 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2011 | 53 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 107 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2017 | 1026 | 0.020 |
Why?
|
| Child | 4 | 2018 | 29154 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 925 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1990 | 82 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 717 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2010 | 17 | 0.020 |
Why?
|
| Phenotype | 3 | 2017 | 6295 | 0.020 |
Why?
|
| Osseointegration | 1 | 2010 | 21 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 5159 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 1031 | 0.020 |
Why?
|
| Bone Substitutes | 1 | 2010 | 15 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2011 | 205 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 209 | 0.020 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2010 | 51 | 0.020 |
Why?
|
| Transforming Growth Factors | 1 | 1989 | 40 | 0.020 |
Why?
|
| Dasatinib | 1 | 2013 | 862 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2011 | 198 | 0.020 |
Why?
|
| Mediastinoscopy | 1 | 2009 | 31 | 0.020 |
Why?
|
| Laminin | 1 | 2010 | 194 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 2522 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 2927 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 4654 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2009 | 22 | 0.020 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2009 | 30 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.020 |
Why?
|
| Patient Safety | 1 | 2015 | 649 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2009 | 57 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 1989 | 74 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 111 | 0.020 |
Why?
|
| Protons | 1 | 2012 | 473 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 195 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2010 | 143 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 649 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2010 | 217 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2010 | 135 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2009 | 96 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2010 | 202 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 93 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 447 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 2009 | 127 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 48 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 589 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 483 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2009 | 186 | 0.020 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2008 | 65 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1994 | 1242 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 545 | 0.020 |
Why?
|
| Integrin-Binding Sialoprotein | 2 | 1999 | 15 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 421 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 621 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 356 | 0.020 |
Why?
|
| Desmin | 1 | 2007 | 63 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 770 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2012 | 652 | 0.020 |
Why?
|
| Dyspnea | 1 | 2011 | 416 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 665 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 263 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 650 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2007 | 36 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2010 | 269 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2011 | 348 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2009 | 576 | 0.020 |
Why?
|
| Infliximab | 1 | 2007 | 130 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 298 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 622 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2013 | 732 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 2007 | 83 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2010 | 690 | 0.020 |
Why?
|
| Asthma | 1 | 2015 | 871 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 1997 | 630 | 0.020 |
Why?
|
| Bronchi | 1 | 2008 | 326 | 0.020 |
Why?
|
| Contrast Media | 1 | 2013 | 1472 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 2738 | 0.020 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2006 | 46 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 580 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 1183 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 938 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 1990 | 943 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 593 | 0.020 |
Why?
|
| Jejunostomy | 1 | 2006 | 52 | 0.020 |
Why?
|
| Osteolysis | 1 | 2006 | 80 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 1021 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 663 | 0.020 |
Why?
|
| Pyrroles | 1 | 2010 | 576 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 184 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 260 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 246 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2009 | 627 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 479 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2008 | 428 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 1503 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 1143 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2006 | 461 | 0.020 |
Why?
|
| Actins | 1 | 2007 | 608 | 0.020 |
Why?
|
| Proteomics | 1 | 2012 | 1380 | 0.020 |
Why?
|
| Amino Acids | 1 | 2007 | 728 | 0.020 |
Why?
|
| Infant | 2 | 2018 | 13310 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 1415 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 1363 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 2084 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2018 | 16273 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2007 | 447 | 0.010 |
Why?
|
| Pyridines | 1 | 2010 | 1244 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 2488 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 747 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2265 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 591 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1985 | 1489 | 0.010 |
Why?
|
| Parathyroid Hormone | 2 | 1994 | 194 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1985 | 576 | 0.010 |
Why?
|
| Mice, Mutant Strains | 2 | 1994 | 634 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 1073 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1985 | 500 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 4320 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 3552 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 205 | 0.010 |
Why?
|
| Cartilage | 1 | 1999 | 128 | 0.010 |
Why?
|
| Autoradiography | 1 | 1997 | 132 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 869 | 0.010 |
Why?
|
| Collagenases | 1 | 1997 | 74 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 6942 | 0.010 |
Why?
|
| Amelogenin | 1 | 1996 | 5 | 0.010 |
Why?
|
| Dental Enamel Proteins | 1 | 1996 | 3 | 0.010 |
Why?
|
| Tooth Calcification | 1 | 1996 | 5 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1997 | 300 | 0.010 |
Why?
|
| RNA Probes | 1 | 1996 | 44 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 4053 | 0.010 |
Why?
|
| Calcitonin | 1 | 1997 | 186 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 521 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1997 | 240 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1997 | 360 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 1995 | 96 | 0.010 |
Why?
|
| Biglycan | 1 | 1994 | 11 | 0.010 |
Why?
|
| Cell Separation | 1 | 1997 | 612 | 0.010 |
Why?
|
| Teriparatide | 1 | 1994 | 11 | 0.010 |
Why?
|
| Genes, fos | 1 | 1994 | 53 | 0.010 |
Why?
|
| Algorithms | 1 | 2006 | 3890 | 0.010 |
Why?
|
| Kinetics | 1 | 1997 | 2049 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 1995 | 228 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1994 | 682 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 408 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1995 | 558 | 0.010 |
Why?
|
| Binding Sites | 1 | 1997 | 2171 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1995 | 749 | 0.010 |
Why?
|
| Brain | 1 | 1985 | 4113 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1995 | 1038 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1990 | 299 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 1581 | 0.010 |
Why?
|
| Culture Media | 1 | 1989 | 319 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1994 | 1271 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1989 | 208 | 0.010 |
Why?
|
| Clone Cells | 1 | 1989 | 555 | 0.000 |
Why?
|
| Cell Line | 1 | 1994 | 5114 | 0.000 |
Why?
|
| Skin | 1 | 1990 | 1259 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1985 | 334 | 0.000 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1994 | 6550 | 0.000 |
Why?
|